ES520526A0 - Procedimiento para la obtencion de derivados de piridina. - Google Patents

Procedimiento para la obtencion de derivados de piridina.

Info

Publication number
ES520526A0
ES520526A0 ES520526A ES520526A ES520526A0 ES 520526 A0 ES520526 A0 ES 520526A0 ES 520526 A ES520526 A ES 520526A ES 520526 A ES520526 A ES 520526A ES 520526 A0 ES520526 A0 ES 520526A0
Authority
ES
Spain
Prior art keywords
radical
procedure
obtaining
patient
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES520526A
Other languages
English (en)
Other versions
ES8401321A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of ES8401321A1 publication Critical patent/ES8401321A1/es
Publication of ES520526A0 publication Critical patent/ES520526A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES520526A 1982-03-13 1983-03-11 Procedimiento para la obtencion de derivados de piridina. Granted ES520526A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823209276 DE3209276A1 (de) 1982-03-13 1982-03-13 Arzneimittel mit antihypoxischer und ischaemie-protektiver wirkung

Publications (2)

Publication Number Publication Date
ES8401321A1 ES8401321A1 (es) 1983-12-16
ES520526A0 true ES520526A0 (es) 1983-12-16

Family

ID=6158230

Family Applications (1)

Application Number Title Priority Date Filing Date
ES520526A Granted ES520526A0 (es) 1982-03-13 1983-03-11 Procedimiento para la obtencion de derivados de piridina.

Country Status (6)

Country Link
US (1) US4497821A (es)
EP (1) EP0088938B1 (es)
JP (1) JPS58167570A (es)
AT (1) ATE19514T1 (es)
DE (2) DE3209276A1 (es)
ES (1) ES520526A0 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3209274A1 (de) * 1982-03-13 1983-09-15 Bayer Ag, 5090 Leverkusen Pyridincarbonsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
JPS58185821U (ja) * 1982-06-02 1983-12-10 日産自動車株式会社 ウインドシ−ルド
DE3410645A1 (de) * 1984-03-23 1985-09-26 Bayer Ag, 5090 Leverkusen L-alkylsubstituierte 1,4-dihydropyridinlactone, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE3424342A1 (de) * 1984-07-03 1986-01-09 Bayer Ag, 5090 Leverkusen 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridin-3,5-dicarbonsaeure-isopropyl-(2-(3-trifluormethylphenoxy)-ethyl)-ester, mehrere verfahren zu seiner herstellung sowie seine verwendung in arzneimitteln
FR2568773B1 (fr) * 1984-08-10 1989-03-03 Sandoz Lab Nouvelles compositions pharmaceutiques administrables par voie nasale
US4659717A (en) * 1985-08-21 1987-04-21 Eli Lilly And Company Dihydropyridines useful in the treatment of angina and stroke
US4990507A (en) * 1985-12-12 1991-02-05 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds, and composition comprising the same
GB8530602D0 (en) * 1985-12-12 1986-01-22 Fujisawa Pharmaceutical Co Heterocyclic compounds
CA1312611C (en) * 1987-07-01 1993-01-12 Yamanouchi Pharmaceutical Co., Ltd. Pyridine derivatives, process for production thereof and pharmaceutical composition containing them
GB8905526D0 (en) * 1989-03-10 1989-04-19 Fujisawa Pharmaceutical Co N-containing heterocyclic compounds,processes for the preparation thereof and composition comprising the same
PT657432E (pt) 1993-12-10 2003-07-31 Bayer Ag 1,4-di-hidropiridinas fenil-substituidas com actividade cerebral
DE4430639A1 (de) 1994-08-29 1996-03-07 Bayer Ag Verwendung von 5-substituierten Pyridin- und Hexahydrochinolin-3-carbonsäurederivaten
CH692199A8 (fr) * 1997-10-09 2002-06-14 Cermol S.A. Composes pyridiques et compositions pharmaceutique
US20050203119A1 (en) * 2003-09-10 2005-09-15 Mitsunori Ono Dihydropyridine compounds for treating or preventing metabolic disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1440647A (fr) * 1963-12-10 1966-06-03 Ciba Geigy Nouveaux agents pesticides
US3907808A (en) * 1971-05-17 1975-09-23 Sterling Drug Inc 1,4-Dihydro-4-oxo-7-pyridyl-3-quinolinecarboxylic acid derivatives
US3922278A (en) * 1972-06-12 1975-11-25 Sterling Drug Inc 4-(3-Nitrophenyl)-3,5-pyridinedicarboxylic acid
GB1552911A (en) * 1975-07-02 1979-09-19 Fujisawa Pharmaceutical Co 1,4 dihydropyridine derivatives and the preparation thereof
DE3023820A1 (de) * 1980-06-25 1982-01-14 Bayer Ag, 5090 Leverkusen 4,4-disubstituierte spiro-1,4-dihydropyridine, ein verfahren zu ihrer herstellung, sowie ihre verwendung als zwischenprodukt

Also Published As

Publication number Publication date
ATE19514T1 (de) 1986-05-15
ES8401321A1 (es) 1983-12-16
EP0088938A1 (de) 1983-09-21
DE3363248D1 (en) 1986-06-05
EP0088938B1 (de) 1986-04-30
DE3209276A1 (de) 1983-09-15
US4497821A (en) 1985-02-05
JPS58167570A (ja) 1983-10-03

Similar Documents

Publication Publication Date Title
ES520441A0 (es) Procedimiento para la obtencion de derivados de piridina.
SE8303208L (sv) Heterocykliska foreningar
ES520526A0 (es) Procedimiento para la obtencion de derivados de piridina.
ES2070186T3 (es) Nuevos derivados de 2,4-diamino-pirimidina-3-oxido y su utilizacion en la prevencion de la caida de los cabellos.
ATE144772T1 (de) Piperazinderivate
FI863488A (fi) Foereningar.
ATE14880T1 (de) Cephalosporinverbindungen und ihre herstellung.
MA19604A1 (fr) Procede de preparation de nouvelles triazoloquinazolones et leurs sels
ES555820A0 (es) Procedimiento para la obtencion de 1-aril-5-alcoxiiminoalquilamino-pirazoles
BR8203704A (pt) Compostos utilizaveis em especial como herbicidas processos para preparacao de tais compostos composicao herbicidas e processo para destruicao seletiva das ervas daninhas das culturas
DE3580795D1 (de) Penem-derivate.
ATE8633T1 (de) Vinyl-3-cephalosporinverbindungen und ihre herstellung.
DE3360122D1 (en) Substituted oximinoacetanilides, method for their preparation as well as their use as pesticides
SE8008279L (sv) Bensylidenderivat
DK367082A (da) Cephalosporinderivater og fremgangsmaade til deres fremstilling
DE3266678D1 (en) Substituted phenylcyclopropanecarboxylic-acid esters, process for their preparation and their use as insecticides
DK501083D0 (da) Semicarbazider, fremgangsmade til deres fremstilling samt deres anvendelse
CH653840GA3 (en) Process for protecting keratin-containing materials from attack by keratin-eating insects and 5-phenylcarbamoylbarbituric acid compounds

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19960603